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 Abstract 
 
Background: The 2013-15 Ebola outbreak was unprecedented due to sustained transmission 
within urban environments and thousands of survivors.  In 2014 the World Health 
Organization stated that there was insufficient evidence to give definitive guidance about 
which body fluids are infectious and when they pose a risk to humans. We report a rapid 
systematic review of published evidence on the presence of filoviruses in body fluids of 
infected people and survivors.  
Methods: Scientific articles were screened for information about filovirus in human body 
fluids. The aim was to find primary data that suggested high likelihood of actively infectious 
filovirus in human body fluids (viral RNA).  Eligible infections were from Marburg virus 
(MARV or RAVV) and Zaire, Sudan, Taï Forest and Bundibugyo species of Ebola. [1] Cause 
of infection had to be laboratory confirmed (in practice either tissue culture or RT-PCR tests), 
or evidenced by compatible clinical history with subsequent positivity for filovirus antibodies 
or inflammatory factors.  Data were extracted and summarized narratively.  
Results: 6831 unique articles were found, and after screening, 33 studies were eligible. For 
most body fluid types there were insufficient patients to draw strong conclusions, and 
prevalence of positivity was highly variable. Body fluids taken >16 days after onset were 
usually negative. In the six studies that used both assay methods RT-PCR tests for filovirus 
RNA gave positive results about 4 times more often than tissue culture.  
Conclusions: Filovirus was reported in most types of body fluid, but not in every sample 
from every otherwise confirmed patient. Apart from semen, most non-blood, RT-PCR 
positive samples are likely to be culture negative and so possibly of low infectious risk. 
Nevertheless, it is not apparent how relatively infectious many body fluids are during or after 
illness, even when culture-positive, not least because most test results come from more severe 
cases. Contact with blood and blood-stained body fluids remains the major risk for disease 
transmission because of the known high viral loads in blood.  
 
Author Summary 
The 2013-15 Ebola outbreak has been much larger and lasted longer than any previous Ebola 
emergence, and is further unusual because of the thousands of survivors left behind.  In 2014 
the World Health Organization stated that lack of evidence made it impossible to give 
confident guidance about which body fluids of Ebola patients or survivors are infectious. This 
review summarises published evidence on presence of Ebola and the closely related Marburg 
virus (filoviruses) in body fluids of infected people and survivors though end July 2015.  
Scientific and other reports were searched for tests to detect filovirus in human body fluids on 
otherwise confirmed cases.  33 reports had relevant test results. Blood products were 
confirmed as likely to be highly infectious among actively ill cases. In actively ill patients, 
filovirus was often found in non-blood body fluids.  However, (apart from in semen), it is 
rare for viable virus to be found in survivors. It is not apparent how relatively infectious most 
body fluids are, due to inconsistencies in testing techniques and lack of data about how much 
virus is present at different points of illness and recovery. 
 
Introduction 
The 2013-15 epidemic of Ebola virus disease in West Africa was the largest recorded 
filovirus outbreak, as well as the first emergence of the Zaire species of Ebola in a high-
density urban setting. It is generally accepted that Ebola is a zoonotic infection whose 
primary reservoir is probably bats [2]. Contact with wildlife generates a small number of 
index patients [2,3], and widespread and sustained disease transmission can follow in 
community settings, with a subsequent high mortality rate [4].The size of the 2013-15 
outbreak increased the need for better understanding of all transmission pathways and 
specific types of exposure. Hence, much of the previous advice and guidelines needs to be 
critically reviewed, particularly with regard to risks within communities.  
It is now generally accepted that both Ebola and the closely related Marburg virus 
diseases, are typically transmitted through direct or indirect contact with body fluids of an 
infected individual [5,6].  The early preferred replication cells for filoviruses are dendritic or 
immune (monocytes and macrophages) [5,7].  After the immune system is overwhelmed then 
the virus can easily invade other bodily systems, causing any bodily fluid to potentially be 
infected.  However, uncertainties still remain about how infectious body fluids are, and when 
they pose a risk [8]. In order to address these concerns the World Health Organization 
released a set of “Q and As” on sanitation concerns during the 2013-15 outbreak [9], which 
also stated that there was insufficient evidence to give definitive guidance. In order to 
undertake an adequate risk assessment, knowledge on the presence of the virus in various 
body fluids is essential. We report a rapid systematic review of the available published 
evidence on the presence of filoviruses in body fluids of infected people and survivors.   
 
Methods  
Searches 
Medline, Scopus and grey literature (Table S1) were searched through 23 July 2015 
with the string filovir*.af. OR ebola.af. OR ebolavir*.af OR Marburg-virus.af, without 
restrictions for date or language.   
 
Inclusion criteria 
The aim was to find primary data that suggested high likelihood of actively infectious 
virus in human body fluids (viral RNA).  Eligible infections were from any of the Marburg 
virus species and Zaire, Sudan, Taï Forest and Bundibugyo species of Ebola.  Species of 
filovirus not known to be dangerous to humans were excluded.  Cause of infection had to be 
laboratory confirmed (culture or polymerase chain reaction/RT-PCR tests), or evidenced by 
compatible clinical history with subsequent positivity for filovirus antibodies or inflammatory 
factors [10].  Such post-disease markers in body fluids were not deemed eligible by 
themselves to confirm cause of disease, because antibodies are widespread in the regional 
population, including in many people with no relevant clinical history [11-15].  
Commentaries, editorials, news reports, protocols or conference presentations were 
excluded. We took it as given that any patient ill with filovirus should have detectable virus 
in blood.  Therefore, studies which only report a single test result on blood for each patient or 
did not indicate the patient(s)’ day of illness were ineligible:  they did not add to our 
objectives of describing viral load change over time in blood, or the likelihood of virus in 
non-blood products. Similarly, articles which reported primary data that were duplicated 
elsewhere were not included. Titles and abstracts were screened for inclusion criteria by a 
single reviewer and verified by a second reviewer. Where abstracts were unavailable, the 
paper was only assessed in full text if the title included at least one of these keywords: 
survive, survival, fluids, viral load, urine, semen, saliva, plasma or blood.  Inclusion of full 
text papers was assessed in duplicate and decision differences at all stages were resolved by 
discussion. Articles were grouped where they reported on the same primary data, to ensure 
patient results were not duplicated. We searched selected papers for further articles relevant 
to our research questions.  
Data were extracted from included studies by a single researcher and verified by a 
second researcher, for patients with confirmed filovirus infection.  Details extracted were: 
bibliographic details, virus species, date and place of outbreak, body fluids tested, number of 
people tested and number of samples, days following disease onset and assay methods.  
A PRISMA checklist [16] is provided (Table S2).  Study validation (Table S3) was 
primarily concerned with reliable confirmation of disease cause and presence of eligible 
filovirus RNA. Validity questions were intended to verify that assay methods were 
appropriate and validated, that specimens were duplicate tested or compared to controls, and 
that samples were handled and stored correctly for a relatively short period before testing (< 2 
weeks, to reduce the risks of specimen degradation). 
Data on virus concentration in blood samples is presented in graphic form. Presence 
or absence of virus in non-blood body fluids was presented as proportion positive with 95% 
confidence intervals. In order to adjust for multiple samples from the same patient, each 
specimen was weighted by the inverse of the number of samples from that patient:  To 
prevent a large number of test results from a small number of patients skewing the predicted 
probability of positivity, each test result was weighted by the inverse of the number of 
samples from that patient. Thus, if ten test results were from one patient, each carried a 
weight of 0.1, but if only one test result existed for another patient, the latter test had a weight 
of 1 in constructing the probability distribution.  Proportions and associated confidence 
intervals (on a Poisson distribution) were calculated using Stats Direct 3 and the results 
presented using fir tree diagrams, for samples taken in the first 16 weeks after onset of illness 
only. 
 
Results 
4926 unique articles were found in Medline and Scopus (Fig 1), and 1905 items were 
found in grey literature.  114 entries were immediately excluded for being conference 
abstracts, protocols, news reports, commentaries or editorials. A further 1603 items lacked an 
abstract.  Most of these appeared to be short commentaries, news summaries and possible 
conference presentations; none contained keywords relevant to our review. Thus, 5114 
references were screened on title and abstract. Of these, 51 articles were chosen for full text 
review, of which one came from the grey literature search (Table S1). Six articles were cited 
by other literature and also eligible for full text review.  Twenty-six articles were excluded 
after full text review for not meeting the eligibility criteria. This left 33 selected articles for 
which data were extracted and summarised (Table 1).  Detailed validity assessment is 
available (Table S3). 
The total number of patients who provided which types of samples in which time 
period cannot be calculated precisely because of imprecise day-of-illness information 
reported in some papers [17-19]. There is also the potential problem that some samples were 
provided by the same patients in different articles (eg [20] and [21], or [22] and [23]).  We 
corrected for this where known and appropriate (to avoid duplicated data being reported 
twice), but there is a small chance that a few patients were double-counted in our totals.  
Nevertheless, some overview comments about data availability can be made with confidence. 
 Apart from saliva and blood, there are potentially important gaps in the information 
on all bodily fluids. There were too few samples to allow strong conclusions to be made for 
breastmilk, vomit or sputum (fewer than 4 patients gave samples, with virus detected in only 
some samples, even during active illness).  There were no semen samples before day 32 of 
illness, and just 17 patients in total provided all semen samples (positivity in first 7 months 
after disease onset = 70%). The patient numbers for eye fluids, skin, sweat or vaginal swabs 
samples before day 17 of illness was just 4-9 individuals.  In contrast, at least 14 patients 
provided samples for each of stools, urine, saliva or blood products by the 16th day of illness.  
In the period through 112 days after onset of illness, between 15 and 45 patients gave eye, 
skin, sweat and vaginal specimens  Saliva and blood drew on samples from 90+ unique 
patients of which at least 70 samples (50+ patients, saliva) and > 200 samples (145+ patients, 
blood) were collected before day 16.  However, after day 16, blood samples were provided by 
just twelve of the uniquely identifiable 145 patients.   
 
 
Fig 1. Study Selection Procedure 
 
 
Table 1. Selected Study Characteristics 
Species, authors Outbreak dates and 
treatment place 
Body fluids tested  
(No. patients : No. samples)  
Assay method(s)  
    
EBOV[11] Sep-Oct 1976, Yambuku, 
Zaire 
Blood (1:10) Platelet counts, antibody titers 
EBOV[24] November 1976, England 
UK 
Blood (1:21) 
Faeces (1:5), Urine (1:7) 
Seminal fluid: (1:5) 
Throat swab: (1:2) 
Cell cultures and microscope examination 
EBOV[25] Yambio, Sudan 1979 Blood and liver samples.  189+ 
specimens tested: 10 cases detailed for 
data extraction 
Vero cells, cavy tissue cultures (virus isolation), 
Sera antibody and isolation of virus in post-
mortem tissues 
    
EBOV[18]  Summer 1995, Kikwit 
DRC 
Blood (50+:465+) Vero cell cultures confirmed by 
antigens/antibodies 
EBOV[21]  2-13 July 1995, Kikwit 
DRC 
Blood products, conjunctival, rectal, 
saliva/oral, seminal, urine, vaginal, (12 
pts:1-4 samples each) during 
convalescence 
RT PCR, cell cultures and genetic sequencing 
EBOV[20] Jun-July 1995, Kikwit 
DRC 
Blood products, tears, sweat, stools, 
saliva/oral, semen, urine, vaginal, 
(28+:300+), mostly convalescents 
Virus isolation, RT-PCR, antigens 
EBOV [26] Oct-Nov 1996, 
Johannesberg SA 
Blood plasma (1:2), semen (1:1) Vero cell culture and unclear but repeated test 
methods, genetic sequencing 
EBOV[27] Early 2003, Kéllé, Cuvette 
Ouest, Congo 
Oral and blood specimens from 24 
cases & 10 controls 
RT-PCR, antigens and antibodies, genetic 
sequencing 
EBOV [28] Jul-Aug 2014, Sierra 
Leone 
Blood (35:38) RT-PCR 
EBOV[29] August 2014, Sierra 
Leone, transfer to 
Germany 
Blood plasma (1:12),  
Sweat (1:19), Urine (1:18) 
RT-PCR and Vero cell cultures 
EBOV [19] Sierra Leone 2014 Blood serum (≥ 6: 266),  
Throat wash (> 1: 49) 
RT-PCR 
    
EBOV [30] Sep-Oct 2014, Sierra 
Leone transfer to 
Frankfurt Germany 
Blood products (1:23), Stool (1:9), 
Urine (1:8), other liquid waste (1:3) 
RT-PCR 
EBOV [22,23,31-
33] 
Jul-Oct 2014, 4 transfers 
from West Africa to USA 
Blood (4:107), Urine/renal waste (1:3) RT-PCR 
EBOV [34] Oct 2014, Spain Blood (1:2), Conjunctival (1:5), Saliva 
(1:6), Sweat (1:6), Stool (1;5), Urine 
(1:5), Vaginal (1:5) 
RT-PCR and Vero cell culture 
EBOV [35] Sep-Oct 2014, Texas USA Blood (3:16), Rectal (1:1), Skin (1:2), 
Sweat (1:1), Throat (1:1), Urine (2:10), 
and Vaginal (2:3) 
qRT-PCR 
EBOV [36] Oct 2014, Liberia transfer 
to USA 
Blood (1:10) RT-PCR 
EBOV[37] Oct 2014, Guinea Urine (1:1), Blood (1:3),  
Breastmilk (1:1) 
RT-PCR 
EBOV [38] West Africa, 2014-2015 Blood (1:4) qRT-PCR 
EBOV [39] Oct-Nov 2014,  
New York City 
Blood (1:3) NAAT 
Species, authors Outbreak dates and 
treatment place 
Body fluids tested  
(No. patients : No. samples)  
Assay method(s)  
EBOV [40] Convalescent detained in 
India 
Semen (1:2) unclear 
EBOV [41] Nov 2014, Monrovia Blood (2:6) RT-PCR 
EBOV [42] Nov 2014, Sierra Leone 
transfer to Switzerland 
Blood (1:12), Conjunctival (1:7), Saliva 
(1:6), Stools/Rectal (1:8), Sweat (1:3), 
Urine (1:11) 
RT-PCR 
EBOV [43] Sept 2014 and March 
2015, Liberia 
Blood (1:2), Semen (1:1) RT-PCR 
EBOV [44] Convalescent in USA, 
March 2015 
Blood (1:2), Conjunctival (1:3), Semen 
(1:1), Urine (1:1) 
RT-PCR 
MARV[45] Sept. 1967, Marburg, 
Germany 
Semen (1:1) Virus antigen in semen, wife contracting disease 
after sexual intercourse and cell culture test to 
confirm wife’s illness 
MARV[46] Sept. 1967, Marburg, 
Germany 
Blood (17:17), Stools (5:5), Throat 
(6:6), Urine (4:4) 
Cell cultures 
MARV[47]  Feb 1975, Johannesburg 
SA   
Fluid aspirated from eye (1:2) Vero cell culture 
    
MARV [48] 2008, Colorado Blood (1:2) RT-PCR and culture 
    
SUDV[17]  2000 
Gulu Uganda 
Breastmilk (1:2), Saliva (10:16), Semen 
(1:2), Sputum (1:2), Stools (4:4), Sweat 
(1:1), Tears (1:1),  Urine (5:11), Vomit 
(1-2:2) 
RT-PCR and virus culture 
    
SUDV[49] 2000-2001, Uganda Blood products, (many pts but only six 
in detail) 
RT-PCR (variants), antigen-capture diagnostic 
assay, plaque assays (Vero cell cultures) 
    
    
    
Notes: RT-PCR = Reverse transcriptase polymerase chain reaction. NAAT = nucleic acid amplification test  , MARV= Marburg virus, 
SUDV = Sudan Ebola, , EBOV = Zaire Ebola. 
 
 
 
 
Body fluid data were found for Marburg (MARV) but not Ravn virus, and for Ebola species 
EBOV and SUDV but not TAFV or BUDV.  Presence of actively infectious virus in body  
fluids was reported in six different ways. Precise viral load was not usually reported, and 
there were problems with the consistency and accuracy of the assay tests used. Hence, virus 
presence in blood is reported in our summary according to assay method (culture, RT-PCR or 
non-specific NAAT) and units given by authors, but with many caveats, and in non-blood 
body fluids are mostly reported as simply positive or negative.  
 
Blood or blood products 
Twenty-nine studies reported on filovirus detection in blood either in a time series for 
individual patients or for a group of five or more patients. 26 articles were concerned with 
Zaire Ebola, two with Marburg virus [46] and one with SUDV Ebola [49]. Many reports 
[n=14; 21,25-27,31,34,35,37,39-41,44,46,48] merely reported presence or absence of viral 
RNA. Six papers gave viral load/concentration in blood as CT values [23,28,32,36,38,43] and  
two articles [11,22] stated tissue-culture infectious dose (TCID50). A 1978 paper reported 
infectious units [24] and five studies gave results in copies per ml [19,29,30,42,49]. Plaque-
forming units (PFU) were also reported [18] .  There was also a mix of detection methods 
(RT-PCR, culture and unspecified NAAT), and some papers gave results for duplicated 
samples by two different assay methods with different units (eg., CT values by RT-PCR and 
presence/absence by culture [23]). Sometimes for reporting purposes, authors converted their 
observed metrics (such as CT values) to another reporting unit (eg., TCID50, [22]). 
Standardising these results to a single measurement unit was problematic.   
Multiplying TCID50 by 0.69 for adults converts to PFU [8] and conversion curves from CT 
values to TCID50 have been produced for Ebola virus [22], but translating a mere 
presence/absence test to other units is less straightforward. Viral loads were often presented 
in imprecise graphic forms [bar charts or scatterplots, 18,29,32,36,42,49]. Confidence 
intervals or ranges for viral load estimates were provided (graphically) in only one paper 
[18]. As a result, most viral loads were somewhat inexact, lacked confidence intervals and are 
not equivalent between patient groups. 
 
Fig 2. Viral load from blood samples in filovirus patients  Key:  pts = patients.  Results are 
for blood or blood products (serum or plasma) until day 24 of illness.  Units are as stated in 
cited articles.  Leftside panels, a.-c.: Culture only detection methods.  Right-side panels d-f: 
RT-PCR detection only.  Bottom chart value = limit of detection (McElroy et al, Kreuels / 
Schibler / Wolf et al and all data in panel d) or implied positivity detection threshold (all 
other sources).  
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 The blood measurements should still indicate when viral loads are probably highest 
and when they are likely to approach undetection. Fig 2 shows viral load information in blood 
or blood products from culture methods (left side panels) or RT-PCR (right side), in the units 
reported by the stated authors, plotted against corresponding day of illness. The limit of 
detection (LoD) is the bottom value on each chart, either stated or implied.  It merits mention 
that the true threshold for detected positivity for CT values (Panel d) may be uncertain.  Most 
authors follow a rule of ≥ 40 cycles but it has been argued that for asymptomatic EBOV 
convalescents, the true LoD may be ≥ 36 cycles.  [23]  Presence/absence data in other articles 
are not shown  in Fig 2 but can be used to observe that overall, only 7 of the 145 individually 
identified patients in our extracted data had detectable virus in blood after day 16 of illness 
(using LoD ≤ 40).  The latest positivity was day 29 of illness, using the criterion that CT 
value ≤ 40.  With a revised CT value detection threshold of 36, the latest date for virus 
detected in blood among patients in our extracted data would be day 20 [22]. .   
 
Fig 3. Probability of positivity for all samples tested by culture through day 110 post 
illness onset.  The numbers in parenthesis after each fluid type indicate the number of 
patients who provided samples for each body fluid.  The numbers on the right side are the 
mean probability for positivity (also shown as a cross mark) with 95% confidence interval in 
parentheses (shown as lines both sides of the cross). 
 
Fig 4. Probability of positivity for all samples tested by RT-PCR through day 110 of 
illness onset.  The numbers in parenthesis after each fluid type indicate the number of 
patients who provided samples for each body fluid.  The numbers on the right side are the 
mean probability for positivity (also shown as a cross mark) with 95% confidence interval in 
parentheses (shown as lines both sides of the cross). 
 
Fig 5. Probability of positivity for all samples tested by RT-PCR days 1-16 of illness 
onset.  The numbers in parenthesis after each fluid type indicate the number of patients who 
provided samples for each body fluid.  The numbers on the right side are the mean 
probability for positivity (also shown as a cross mark) with 95% confidence interval in 
parentheses (shown as lines both sides of the cross). 
 
Fig 6. Probability of positivity for all samples tested by RT-PCR days 17-110 of illness 
onset.  The numbers in parenthesis after each fluid type indicate the number of patients who 
provided samples for each body fluid.  The numbers on the right side are the mean 
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probability for positivity (also shown as a cross mark) with 95% confidence interval in 
parentheses (shown as lines both sides of the cross). 
 
 
 
 
Other body fluids 
Twenty two papers reported on the presence of filovirus in non-blood body fluids, 
three of which concerned Marburg virus [45-47], one SUDV [17] and the remainder Zaire 
Ebola. The proportions of positive samples are illustrated in Figures 3-6, grouped by testing 
method or date (before day 113 after onset of illness).  The numbers in parenthesis after each 
fluid type indicate the number of patients who provided samples for each body fluid.  The 
numbers on the right side are the mean probability for positivity (also shown as a cross mark) 
with 95% confidence interval in parentheses (shown as lines both sides of the cross).  
We distinguish between results from culture (Fig 3) or by RT-PCR (Fig 4).  RT-PCR 
results are further divided into all early samples (Fig 5, <17 days after onset of illness) or all 
late samples (Fig 6, >16 days after onset of illness).  Days 16/17 are an imperfectly identified 
typical transition point from active illness to convalescence, because our included papers 
often did not identify the last date of viraemia or active illness.  We observe that blood 
samples are rarely positive on days 17-112 (Fig 2; virus was detected in blood of just 7 of 145 
individuals who can be individually identified in our extracted data). Most deaths from Ebola 
virus disease occur by day 16 of illness  [50,51]; the latest individually identified death in our 
dataset was on day 16 of illness [27].   
Overall, body fluid samples tested by RT-PCR (Fig 4) are about four times more 
likely to test positive than those tested by culture (Fig 3). This approximate discrepancy also 
exists among the six studies that provided duplicated results by both culture and RT-PCR 
[17,20,21,29,34,44].  Results for saliva and other oral fluids are particularly in disagreement 
(less than 5% positive by culture and almost 50% positive by RT-PCR). Virus was detected 
13 
 
in most breastmilk samples, but the dataset is too small (three samples from two patients) to 
be conclusive.  Data on seminal fluid are the most consistent between assay methods, with a 
mean weighted probability of 21% positivity for culture before day 113, and 28% for RT-
PCR.  Virus was detected in 73% of seminal fluid samples from 26 samples provided by 18 
survivors before day 113.  The latest positive result (in seminal fluid) was 203 days after 
onset of illness, but no results were available for days 111 to 202 or days 204 to 696 after 
onset of disease. Filovirus was not detected in seminal fluid of six survivors at 697-707 days 
post-illness [20,21].  
 Probability of detection by RT-PCR in different body fluids is shown before day 17 
(Fig 5) and after day 16 (Fig 6).  The small number of patients providing samples leads to 
large confidence intervals for most body fluids.  Saliva is unusual in being provided from 
over 50 patients in both the early and late monitoring periods which leads to smaller 
confidence intervals.  The probability of virus detection in saliva was fairly similar in both 
periods, falling only modestly from 55% to 45% before and after 16 days of illness.   
Specific viral load data were usually not provided for non-blood samples.  From the 
limited available viral load data, it seems that viral loads can be high or may be almost 
negligible in non-blood body fluids (high viral load is much more likely to be detected in 
blood).  For instance, very low viral loads were reported in urine (CT values = 36-40+) even 
when patients had high viraemia [32,33].  For stools or rectal swabs from symptomatic 
patients, virus was not detected in Kreuels et al [29] but viral load in stools was relatively 
high in two other patients (maximum log 105 - 105.5 copies/ml: [30,42]).  High viral loads for 
saliva were found in some studies (on days 1-8, lowest CT value = 21, maximum log 105.5 – 
106.3 copies/ml: [19,38,42]), but virus was undetected in saliva of other patients on days 9-16 
of illness [21,24,35,42]. 
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Discussion 
We report the first systematic review to investigate the probability of different body 
fluids being positive for African filoviruses. We summarize evidence about presence and 
persistence [52] of infectious virus in each body fluid compared to point of onset of illness, 
which is especially important information when managing disease transmission risks during a 
large outbreak where there may be many survivors. We provide quantitative estimates of the 
probability of positivity. Our main finding is that blood from infected patients is likely to be 
positive for the virus but rarely later than 16 days after the onset of illness. Titres in blood can 
very high, - up to about 108 viruses/ml; it seems that survival is related to the maximum virus 
titre [49,53-56]. Many other body fluids are much less likely to be positive, particularly when 
tested by tissue culture.  Although viral loads can be high in some body fluids, virus may be 
completely undetected, even during active illness.  An exception is semen samples, which 
tended to consistently test positive regardless of whether assay method was RT-PCR or 
culture. 
Infected blood continues to appear to be the most infectious body fluid because it is 
the body fluid that most consistently tests positive during illness, and viral loads are often 
observed to be very high.  High viral loads are less consistently reported in other bodily 
fluids.  Disease following contact with infected blood is well-documented [11,15,24,57]. 
Disease transmission from contact with non-blood product body fluids has not been described 
as clearly, and may depend to some extent on whether the fluid is contaminated with blood 
(visible or not). Given the known propensity of patients to haemorrhage in later disease, 
contamination is a plausible explanation.  The likelihood of disease transmission also 
depends on possible difficulties in containing and disposing of potentially hazardous 
material: such as explosive diarrhea, which was said to be a feature of the 2013-15 Ebola 
outbreak [31,55].  
15 
 
 
It is noteworthy that patients have been released from hospital when asymptomatic 
(especially without viraemia) in spite of detected virus in saliva, sweat or urine [29,42] 
because it was not possible to cultivate virus swabbed from these areas in tissue culture. 
These results may therefore indicate that recalibration of the threshold for detecting positivity 
in at least some filovirus RT-PCR tests in some contexts is advisable (as argued by Spengler 
et al [23]). It also merits mention that testing usually discontinues on individuals who have 
already had repeat negative results. Therefore, what Figures 3-6 show is not the likelihood of 
positivity among all patients or survivors, but rather among those cases for whom positivity is 
still suspected. 
 It is also not clear how RT-PCR positivity relates to infectiousness in the absence of a 
positive culture. Viral RNA can be detected for some time after virus is inactivated [58]. Six 
of our included studies [17,20,21,29,34,44] suggest that perhaps only about 25% of RT-PCR 
filovirus-positive samples are infectious.   
Two case histories are relevant to human milk exposure, from mother-infant pairs 
[37]. Both infants were under six months old. Although one mother tested negative in blood 
and breastmilk for Ebola virus disease (EVD), she was highly symptomatic and her urine 
tested positive for viral RNA as did her baby (blood test) who subsequently died of EVD, 
having had 13 days of (not exclusive) breastfeeding during his mother’s active illness. A 
second breastfeeding mother produced a positive test (blood) for Ebola and highly 
symptomatic, but her infant (exclusively breastfed for first six days of mother’s illness) did 
not develop EVD. It is possible that breastmilk alone from mothers with EVD poses low 
disease transmission risks to unweaned babies. The immunological components in human 
milk are complex and can reduce transmission of viral diseases from the mother [59]. The 
chances of EVD transmission from breastmilk alone may be similar to the very low risks of 
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HIV transmission to exclusively breastfed babies [60], risks that rise sharply after the infant 
starts solids. However, a key difference between HIV and EVD transmission is that close 
physical contact with the ill mother may mean exposure to other highly infectious bodily 
fluids from EVD, especially during the most severe stages of illness. The authors of the 
mother-infant pair case histories highlighted the possible inconsistencies and importance of 
multiple tests in clinical environments to confirm absence of filovirus infection. 
World Health Organisation advice is now that male survivors should adopt barrier 
methods during sexual contact for at least six months following end of illness [61]. 
Preliminary monitoring [62] strongly suggests that six months is still inadequate; prospective 
studies [63,64] are under way to gather better evidence about residual virus in seminal 
products.  An epidemiological account by Christie et al [43] describes disease transmission to 
just one of two sexual partners of an EVD survivor; this chain of transmission and recent 
monitoring evidence [62] both suggest that viral load in semen of convalescents is often low 
and may even be sporadic.  Low virus load in semen of an EBOV survivor was also reported 
in Emond et al [24]. 
One study [38] reported on viral shedding before illness and it seems likely that many 
body fluids are infectious during at least late incubation. In several cases where virus 
shedding during incubation was suspected [11,37,65] or shown [38], the incubating patient 
was either heavily pregnant or in childbirth.  It is suspected that immuno-suppression 
associated with pregnancy can lead to delayed disease onset.  Otherwise, data about possible 
disease transmission from asymptomatic persons are inconclusive [13,20]. There is 
widespread filovirus antibody seroprevalence in central Africa (2-15% of the population) 
without history of relevant illness [11-15] suggesting exposure mechanism(s) that can lead to 
infection without disease. The implications of potentially widespread asymptomatic infection, 
or the mechanism that lead to it, are unknown. Better understanding of the consequences of 
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low dose exposure that presumably leads to asymptomatic infection, might help to improve 
disease resistance or to identify optimal intervention points when targeting resources during 
disease outbreaks. Infection without disease is intriguing.  EVD resulted in non-human 
primates which were inoculated with as few as four virions [66], and from aerosol exposure 
to PFU (log10) 2.6 concentrations of organisms [67]. But it is unclear what the threshold for 
filovirus infectious dose is in actual community outbreaks among humans [66,68].    
Some of the most recent studies in our review discord with older research but also 
agree with established guidance that was only weakly supported by older studies. For 
instance, although official guidance has long stated [69] that filovirus was in sweat and any 
other body fluid, until recently viral RNA was never reported in sweat [15], it still hasn’t 
been reported in vomit, and is often not found in many other body fluids. Inconsistent test 
results between selected studies can perhaps also be interpreted with respect to our 
assessment of validity and study quality. All selected studies used appropriate and clearly 
described testing techniques, and nearly all used confirmation strategies (multiple tests, 
different types of tests or laboratories on duplicate specimens and/or healthy controls) to 
verify results. Most samples were tested relatively quickly (within two weeks), although there 
was lack of clarity about the test timescale in some papers. The only recurring concern about 
data collection is that many authors in African environments reported challenges 
[17,20,21,27,49] in preserving specimen quality (especially preventing breaks in the cold 
storage chain). These problems may have resulted in some unreliable results [37].  Within our 
review, virus in non-blood products was often detected by RT-PCR among patients treated in 
high resource (western) hospital environments [23,29,30,33-35,44].  However, even when 
RT-PCR suggested positivity, detection by culture in duplicated samples within this group 
was repeatedly not possible, which was interpreted by clinicians and authors as a very low 
risk of actual infectivity from these samples of non-blood body fluids [23,29,34]. New data 
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emerging from the most recent outbreaks should adhere to more rigorous storage and testing 
procedures and thus further clarify the likelihood of infectious virus in specific body fluids.  
 
Limitations 
It is very hard for any systematic review to be fully up-to-date so soon after a large 
outbreak.  Our search only covers research published on and before 23 July 2015. It is not 
desirable, however, to wait until all data from the 2014-2015 epidemic are available because 
the scientific information may be needed soon to help manage the next outbreak.    
 There were biases in how body fluid data were collected.  Surveys exist among 
convalescents regardless of severity of original disease or possible sequelae [20,21], but 
many data collected after day 16 were on patients who were not representative of most 
patients in a filovirus outbreak.  Many samples after day 16 came from a small number of 
patients treated in high resource (western) hospitals; these samples were more likely to have 
virus detected than samples from patients in Africa.  It may be reasonable to assume samples 
collected in in an outbreak area were less reliably stored or processed, and therefore more 
likely to incorrectly find no virus detected.  However, data were also more likely to be 
collected from patients still exhibiting symptoms (treated at any location), especially 
viraemia, whereas all testing stopped on patients who recovered quickly.  Thus, test results 
tend to only be available for those who recently tested positive.  This bias in patient sample 
recruitment falsely elevates the apparent probability of late positivity seen in our results.  
Further difficulties with the reliability of the detection tests include the ever present 
possibility of false positives by any method, the contradictory results reported from different 
test assay methods on identical samples (especially culture vs. RT-PCR), changes in the 
sensitivity of test methods over time (especially for RT-PCR), or indeed the uncertainty about 
19 
 
the appropriate threshold for correct CT values to use when deciding the threshold for 
detecting positivity [23]. 
 
Conclusions 
Filovirus has been found in most types of body fluid, but not every sample from every 
symptomatic patient. Furthermore, with the exception of semen, most non-blood, RT-PCR 
positive samples are likely to be culture negative and so of low infectious risk. Nevertheless, 
it is not apparent how relatively infectious many body fluids are, even when culture positive, 
not least because viral loads are uncertain. The consistency of high viral loads detected in 
blood during active illness suggests that blood and blood-stained body fluids will remain the 
body fluid most often associated with disease transmission.  
 
Acknowledgements 
Our sincere thanks who three anonymous reviewers who diligently read and commented on 
previous drafts of this article. 
 
Supporting Information 
Table S1. Grey literature sources and selections 
Table S2.  PRISMA checklist 
Table S3. Study Quality and Validity Assessment 
 
 
References 
1. Bukreyev AA, Chandran K, Dolnik O, Dye JM, Ebihara H, et al. (2014) Discussions and decisions of 
the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae study 
group, January 2012–June 2013. Archives of virology 159: 821-830. 
2. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez J-P, et al. (2009) Human Ebola outbreak 
resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. 
Vector Borne and Zoonotic Diseases 9: 723-728. 
20 
 
3. Milleliri J, Tevi-Benissan C, Baize S, Leroy E, Georges-Courbot M (2004) [Epidemics of Ebola 
haemorrhagic fever in Gabon (1994-2002). Epidemiologic aspects and considerations on 
control measures]. Bulletin de la Societe de pathologie exotique (1990) 97: 199-205. 
4. Kawaoka Y (2005) How Ebola virus infects cells. New England Journal of Medicine 352: 2645-2646. 
5. Feldmann H, Geisbert TW (2011) Ebola haemorrhagic fever. Lancet 377: 849-862. 
6. Brainard J, Hooper L, Pond K, Edmunds K, PR H (in press) Risk factors for transmission of Ebola or 
Marburg virus disease: a systematic review and meta-analysis. International Journal of 
Epidemiology. 
7. Zampieri CA, Sullivan NJ, Nabel GJ (2007) Immunopathology of highly virulent pathogens: insights 
from Ebola virus. Nature immunology 8: 1159-1164. 
8. Bibby K, Casson LW, Stachler E, Haas CN (2014) Ebola virus persistence in the environment: State 
of the knowledge and research needs. Environmental Science & Technology Letters. 
9. WHO (2014) Ebola Virus Disease (EVD): Key questions and answers concerning water, sanitation 
and hygiene. In: Organisation WH, editor. WHO/EVD/WSH/14. 
10. Wahl-Jensen V, Kurz S, Feldmann F, Buehler LK, Kindrachuk J, et al. (2011) Ebola virion 
attachment and entry into human macrophages profoundly effects early cellular gene 
expression. PLoS Negl Trop Dis 5: e1359-e1359. 
11. Burke J, Declerq R, Ghysebrechts G, Pattyn S, Piot P, et al. (1978) Ebola hemorragic-fever in Zaire, 
1976 - Report of an International Commission. Bulletin of the World Health Organization 56: 
271-293. 
12. Jezek Z, Szczeniowski M, Muyembe-Tamfum J, McCormick J, Heymann D (1999) Ebola between 
outbreaks: intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of 
the Congo, 1981–1985. Journal of Infectious Diseases 179: S60-S64. 
13. Leroy E, Baize S, Volchkov V, Fisher-Hoch S, Georges-Courbot M, et al. (2000) Human 
asymptomatic Ebola infection and strong inflammatory response. Lancet 355: 2210-2215. 
14. Nkoghe D, Padilla C, Becquart P, Wauquier N, Moussavou G, et al. (2011) Risk factors for Zaire 
ebolavirus–specific IgG in rural Gabonese populations. Journal of Infectious Diseases 204: 
S768-S775. 
15. Kuhn J, Calisher CH (2008) Filoviruses: a compendium of 40 years of epidemiological, clinical, and 
laboratory studies: Springer Science & Business Media. 
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that evaluate health care 
interventions: explanation and elaboration. Annals of internal medicine 151: W-65-W-94. 
17. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, et al. (2007) Assessment of the risk of 
Ebola virus transmission from bodily fluids and fomites. Journal of Infectious Diseases 196: 
S142-S147. 
18. Ksiazek T, Rollin P, Williams A, Bressler D, Martin M, et al. (1999) Clinical virology of Ebola 
hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF 
patients in Kikwit, Democratic Republic of the Congo, 1995. Journal of Infectious Diseases 
179: S177-S187. 
19. Liu L, Sun Y, Kargbo B, Zhang C, Feng H, et al. (2015) Detection of Zaire Ebolavirus by Real-Time 
Reverse Transcription-Polymerase Chain Reaction, Sierra Leone, 2014. Journal of Virological 
Methods 222: 62-65. 
20. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum J, et al. (1999) Clinical, virologic, and 
immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their 
household contacts, Kikwit, Democratic Republic of the Congo. Journal of Infectious Diseases 
179: S28-S35. 
21. Rodriguez L, De Roo A, Guimard Y, Trappier S, Sanchez A, et al. (1999) Persistence and genetic 
stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 
1995. Journal of Infectious Diseases 179: S170-S176. 
21 
 
22. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, et al. (2015) Human Ebola virus 
infection results in substantial immune activation. Proceedings of the National Academy of 
Sciences of the United States of America 112: 4719-4724. 
23. Spengler JR, McElroy AK, Harmon JR, Ströher U, Nichol ST, et al. (2015) Relationship Between 
Ebola Virus Real-Time Quantitative Polymerase Chain Reaction–Based Threshold Cycle Value 
and Virus Isolation From Human Plasma. Journal of Infectious Diseases: jiv187. 
24. Emond R, Evans B, Bowen E, Lloyd G (1977) A case of Ebola virus infection. British Medical 
Journal 2: 541-544. 
25. Baron RC, McCormick JB, Zubeir OA (1983) Ebola virus disease in southern Sudan: hospital 
dissemination and intrafamilial spread. Bulletin of the World Health Organization 61: 997. 
26. Richards GA, Murphy S, Jobson R, Mer M, Zinman C, et al. (2000) Unexpected Ebola virus in a 
tertiary setting: clinical and epidemiologic aspects. Critical care medicine 28: 240-244. 
27. Formenty P, Leroy EM, Epelboin A, Libama F, Lenzi M, et al. (2006) Detection of Ebola virus in 
oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of 
Congo. Clinical Infectious Diseases 42: 1521-1526. 
28. Strecker T, Palyi B, Ellerbrok H, Jonckheere S, de Clerck H, et al. (2015) Field evaluation of 
capillary blood samples as a collection specimen for the rapid diagnosis of Ebola virus 
infection during an outbreak emergency. Clinical Infectious Diseases: civ397. 
29. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, et al. (2014) A case of 
severe Ebola virus infection complicated by gram-negative septicemia. New england journal 
of medicine 371: 2394-2401. 
30. Wolf T, Kann G, Becker S, Stephan C, Brodt H-R, et al. (2015) Severe Ebola virus disease with 
vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385: 
1428-1435. 
31. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, et al. (2015) The use of TKM-100802 
and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clinical 
Infectious Diseases: civ334. 
32. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, et al. (2014) Clinical care of two patients with 
Ebola virus disease in the United States. New England Journal of Medicine 371: 2402-2409. 
33. Connor MJ, Kraft C, Mehta AK, Varkey JB, Lyon GM, et al. (2014) Successful delivery of RRT in 
Ebola virus disease. Journal of the American Society of Nephrology: ASN. 2014111057. 
34. Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, de la Calle F, Borobia AM, et al. (2015) Acute 
respiratory distress syndrome after convalescent plasma use: treatment of a patient with 
Ebola virus disease contracted in Madrid, Spain. Lancet Respiratory Medicine 3: 554-562. 
35. Liddell AM, Davey Jr RT, Mehta AK, Varkey JB, Kraft CS, et al. (2015) Characteristics and clinical 
management of a cluster of 3 patients with Ebola virus disease, including the first 
domestically acquired cases in the United States. Annals of internal medicine Online from 12 
May 2015. 
36. Florescu DF, Kalil AC, Hewlett AL, Schuh AJ, Stroher U, et al. (2015) Administration of 
Brincidofovir and Convalescent Plasma in a Patient with Ebola Virus Disease. Clinical 
Infectious Diseases: civ395. 
37. Moreau M, Spencer C, Gozalbes J, Colebunders R, Lefevre A, et al. (2015) Lactating mothers 
infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. Euro surveillance 
20: 3. 
38. Akerlund E, Prescott J, Tampellini L (2015) Shedding of Ebola Virus in an Asymptomatic Pregnant 
Woman. New England Journal of Medicine 372: 2467-2469. 
39. Yacisin K, Balter S, Fine A, Weiss D, Ackelsberg J, et al. (2015) Ebola virus disease in a 
humanitarian aid worker-new york city, october 2014. MMWR: Morbidity and mortality 
weekly report 64: 321-323. 
40. Express News Service (2014) ‘Cured’ of Ebola disease in Liberia, Indian man isolated in Delhi after 
a positive test The Indian Express. 
22 
 
41. Wong KK, Perdue CL, Malia J, Kenney JL, Peng S, et al. (2015) Supportive care of the first two 
Ebola virus disease patients at the Monrovia Medical Unit. Clinical Infectious Diseases: 
civ420. 
42. Schibler M, Vetter P, Cherpillod P, Petty TJ, Cordey S, et al. (2015) Clinical features and viral 
kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infectious 
Diseases Available online from 19 July 2015. 
43. Christie A, Davies-Wayne GJ, Cordier-Lasalle T, Blackley DJ, Laney AS, et al. (2015) Possible sexual 
transmission of Ebola virus—Liberia, 2015. MMWR: Morbidity and Mortality Weekly Report 
64: 1-3. 
44. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, et al. (2015) Persistence of Ebola Virus in 
Ocular Fluid During Convalescence. New England Journal of Medicine 372: 2423-2427. 
45. Martini G, Schmidt H (1968) Spermatogene Übertragung des "Virus Marburg" (Spermatogenesis 
Transmission of Marburg Virus). Klinische Wochenschrift 46: 398-400. 
46. Martini G (1973) Marburg virus disease. Postgraduate medical journal 49: 542-546. 
47. Gear S, Cassel GA, Gear AJ, Trappler B, Clausen L, et al. (1975) Outbreak of Marburg virus disease 
in Johannesburg. British Medical Journal 4: 489-493. 
48. Fujita N, Miller A, Miller G, Gershman K, Gallagher N, et al. (2009) Imported case of Marburg 
hemorrhagic fever-Colorado, 2008. MMWR: Morbidity and Mortality Weekly Report 58: 
1377-1381. 
49. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, et al. (2004) Rapid diagnosis of Ebola 
hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of 
patient viral load as a predictor of outcome. Journal of virology 78: 4330-4341. 
50. Büttner S, Koch B, Dolnik O, Eickmann M, Freiwald T, et al. (2014) Extracorporeal Virus 
Elimination for the Treatment of Severe Ebola Virus Disease-First Experience with Lectin 
Affinity Plasmapheresis. Blood purification 38: 286-291. 
51. Singh SK, Ruzek D (2014) Viral hemorrhagic fevers. Boca Raton, LA: CRC Press, Taylor and Francis 
Group. 444 p. 
52. Boldogh I, Albrecht T, Porter DD (1996) Persistent viral infections. In: Baron S, editor. Medical 
Microbiology. Galveston TX: University of Texas Medical Branch at Galveston. 
53. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, et al. (2014) Biomarker correlates of 
survival in pediatric patients with Ebola virus disease. Emerging infectious diseases 20: 1683. 
54. Bah EI, Lamah M-C, Fletcher T, Jacob ST, Brett-Major DM, et al. (2015) Clinical presentation of 
patients with Ebola virus disease in Conakry, Guinea. New England Journal of Medicine 372: 
40-47. 
55. Fedson DS, Rordam OM (2015) Treating Ebola patients: a ‘bottom up’approach using generic 
statins and angiotensin receptor blockers. International Journal of Infectious Diseases 36: 
80-84. 
56. Fitzpatrick G, Vogt F, Gbabai OBM, Decroo T, Keane M, et al. (2015) The contribution of Ebola 
viral load at admission and other patient characteristics to mortality in a Médecins Sans 
Frontières (MSF) Ebola Case Management Centre (CMC), Kailahun, Sierra Leone, June–
October, 2014. Journal of Infectious Diseases: jiv304. 
57. Francesconi P, Yoti Z, Declich S, Onek PA, Fabiani M, et al. (2003) Ebola hemorrhagic fever 
transmission and risk factors of contacts, Uganda. Emerging infectious diseases 9: 1430. 
58. Rodríguez RA, Pepper IL, Gerba CP (2009) Application of PCR-based methods to assess the 
infectivity of enteric viruses in environmental samples. Applied and Environmental 
Microbiology 75: 297-307. 
59. Thormar H, Isaacs C, Brown H, Barshatzky M, Pessolano T (1987) Inactivation of enveloped 
viruses and killing of cells by fatty acids and monoglycerides. Antimicrobial agents and 
chemotherapy 31: 27-31. 
23 
 
60. Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, et al. (2007) Mother-to-child 
transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an 
intervention cohort study. Lancet 369: 1107-1116. 
61. World Health Organisation (2015) Interim advice on the sexual transmission of the Ebola virus 
disease. Sexual and reproductive health. 
62. Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, et al. (2015) Ebola RNA persistence in semen 
of Ebola virus disease survivors—preliminary report. New England Journal of Medicine [Epub 
ahead of print]. 
63. (2015) Study of Ebola survivors opens in Liberia. In: Routh J, editor. Trial to examine long-term 
health effects of Ebola virus disease: National Institutes of Health. 
64. Anonymous (2015) Sierra Leone launches Ebola survivor sex study GBCGhana. 
65. MacNeil A, Farnon EC, Morgan OW, Gould P, Boehmer TK, et al. (2011) Filovirus outbreak 
detection and surveillance: lessons from Bundibugyo. Journal of Infectious Diseases 204: 
S761-S767. 
66. Geisbert TW, Jahrling PB, Larsen T, Davis KJ, Hensley L (2002) Filovirus pathogenesis in 
nonhuman primates. DTIC Document. 
67. Johnson E, Jaax N, White J, Jahrling P (1995) Lethal experimental infections of rhesus monkeys by 
aerosolized Ebola virus. International journal of experimental pathology 76: 227. 
68. Nakayama E, Saijo M (2013) Animal models for Ebola and Marburg virus infections. Frontiers in 
microbiology 4. 
69. World Health Organisation (2015) Ebola virus disease: Fact Sheet No. 103. 
 
 
